Darbepoetin-alpha prevents progressive left ventricular dysfunction and remodeling in nonanemic dogs with heart failure.

@article{Rastogi2008DarbepoetinalphaPP,
  title={Darbepoetin-alpha prevents progressive left ventricular dysfunction and remodeling in nonanemic dogs with heart failure.},
  author={Sharad Rastogi and Makoto Imai and Victor G. Sharov and Sudhish Mishra and Hani N. Sabbah},
  journal={American journal of physiology. Heart and circulatory physiology},
  year={2008},
  volume={295 6},
  pages={H2475-82}
}
In anemic patients with heart failure (HF), erythropoietin-type drugs can elicit clinical improvement. This study examined the effects of chronic monotherapy with darbepoetin-alpha (DARB) on left ventricular (LV) function and remodeling in nonanemic dogs with advanced HF. HF [LV ejection fraction (EF) approximately 25%] was produced in 14 dogs by intracoronary microembolizations. Dogs were randomized to once a week subcutaneous injection of DARB (1.0 microg/kg, n=7) or to no therapy (HF, n=7… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 48 references

Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia

  • DJ van Veldhuisen, K Dickstein, +6 authors P. Ponikowski
  • Eur Heart J
  • 2007
2 Excerpts

Similar Papers

Loading similar papers…